Preclinical studies evaluating the activity of NEDD8 activating enzyme (NAE) inhibition on miR-155 expression in AML cell lines demonstrated that miR-155 could be downregulated through disruption of binding of NF-KB to the miR-155 promoter, suggesting that NEDD8 inhibitors, such as pevonedistat, may be novel treatment options for AML associated with high miR-155 expression (42). This evidence concerns the gene NFKB1 and acute myeloid leukemia.